Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research DOI Open Access
Mariona Pont, Marta Marqués, Anabel Sorolla

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13518 - 13518

Published: Dec. 17, 2024

Triple-negative breast cancer (TNBC) represents roughly one-sixth of all patients, but accounts for 30–40% deaths. Due to the lack typical biomarkers exploited clinically cancer, it remains very difficult treat. Moreover, its intrinsic high heterogeneity and proneness become resistant drugs administered makes treatment management challenging oncologists. Herein, we outline different therapies used currently TNBC list ongoing clinical trials provide an overview most recent therapeutic landscape. In addition, highlight emerging in preclinical stage that hold promise, such as epigenetic modulators, CRISPR, miniproteins, radioconjugates, vaccines, PROTACs. navigate through existing limitations challenges which hamper development new more effective treatments TNBC. Lastly, point directions may revolutionize future therapy

Language: Английский

Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies DOI Open Access

Valencia Mc Neil,

Seung Won Lee

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1408 - 1408

Published: April 23, 2025

A groundbreaking milestone in oncology has been the recognition and targeted elimination of malignant cells through cancer immunotherapy, which harnesses body’s immune system to attack [...]

Language: Английский

Citations

0
Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research DOI Open Access
Mariona Pont, Marta Marqués, Anabel Sorolla

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13518 - 13518

Published: Dec. 17, 2024

Triple-negative breast cancer (TNBC) represents roughly one-sixth of all patients, but accounts for 30–40% deaths. Due to the lack typical biomarkers exploited clinically cancer, it remains very difficult treat. Moreover, its intrinsic high heterogeneity and proneness become resistant drugs administered makes treatment management challenging oncologists. Herein, we outline different therapies used currently TNBC list ongoing clinical trials provide an overview most recent therapeutic landscape. In addition, highlight emerging in preclinical stage that hold promise, such as epigenetic modulators, CRISPR, miniproteins, radioconjugates, vaccines, PROTACs. navigate through existing limitations challenges which hamper development new more effective treatments TNBC. Lastly, point directions may revolutionize future therapy

Language: Английский

Citations

3